New President Appointed for Nitto Denko Avecia Inc.

Ms. Cooper has an extensive background in the pharmaceutical space, starting her career as a Manufacturing Formulation Chemist for small molecules. She joined Nitto Avecia 19 years ago and has served in roles of increased responsibility in marketing, business development and project management. Most recently she has served as the Vice President, Business Development and played a critical role on Nitto Avecia's leadership team during the company's most recent period of rapid growth.    Ms...
MILFORD, Mass., (informazione.it - comunicati stampa - salute e benessere)

Ms. Cooper has an extensive background in the pharmaceutical space, starting her career as a Manufacturing Formulation Chemist for small molecules. She joined Nitto Avecia 19 years ago and has served in roles of increased responsibility in marketing, business development and project management. Most recently she has served as the Vice President, Business Development and played a critical role on Nitto Avecia's leadership team during the company's most recent period of rapid growth.   

Ms. Cooper states: "I am deeply honored to serve as the first female president of Nitto Avecia. I am inspired by the limitless possibilities ahead for our company and the dedication, resilience, and commitment of our employees. Through our culture of innovation, we will continue to bring the development and manufacturing of oligonucleotides to new heights of success."

Mr. Terada states: "There is an extremely positive outlook for the oligonucleotide market with great opportunities for Nitto Avecia, and Nitto Avecia Pharma Services to partner with our customers on life changing and life-saving pharmaceuticals. I look forward to continuing to work with this exceptional team as we contribute to patients and the oligonucleotide market."

Mr. Terada and Ms. Cooper will be based at the Nitto Avecia headquarters in Milford, MA.

ABOUT NITTO DENKO AVECIA INC.
Nitto Denko Avecia Inc., is a recognized leader in development and manufacturing services of oligonucleotide therapeutics with facilities in Milford, MA, and Cincinnati, OH and with Nitto Avecia Pharma Services in Irvine, CA that cover preclinical to commercial needs. The company has manufactured more than 1,200 oligonucleotide sequences and developed an extensive late phase portfolio and is the first CDMO to offer a comprehensive, end-to-end oligonucleotide solution. More information: www.Avecia.com.

New President Appointed for Nitto Denko Avecia Inc.

ABOUT NITTO DENKO CORPORATION
Founded in 1918, Nitto is Japan's leading materials manufacturer, offering over 13,500 diversified industrial products to more than 70 business fields as electronics, automobiles, ecology, and life science. Nitto Denko is committed to innovating in a customer-oriented manner.  Under the brand slogan "Innovation for Customers," Nitto Denko "aim[s] to become an essential top ESG Company that continually brings amazement and inspiration." More information: www.Nitto.com

For additional information, please contact:

Keri Dufault, Senior Director, Business Development and Marketing, Nitto Denko Avecia Inc. [email protected]

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/new-president-appointed-for-nitto-denko-avecia-inc-302128687.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili